{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:36:38Z","timestamp":1783568198954,"version":"3.55.0"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021LZY002"],"award-info":[{"award-number":["ZR2021LZY002"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010669","name":"Department of Health of Shandong Province","doi-asserted-by":"publisher","award":["RC2021002-23"],"award-info":[{"award-number":["RC2021002-23"]}],"id":[{"id":"10.13039\/501100010669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Anakinra and canakinumab are two FDA-approved IL-1 blockers indicated for the treatment of multiple autoinflammatory diseases, yet their safety has not been comprehensively analyzed. We aimed to assess the safety signals associated with anakinra and canakinumab by conducting a pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adverse reaction data spanning from the first quarter of 2004 to the fourth quarter of 2023 was downloaded from the FAERS database. A disproportionality analysis utilizing various methods, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and Empirical Bayes Geometric Mean (EBGM), was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Anakinra and canakinumab were identified as the primary suspect drugs for adverse events (AEs) in 7,544 and 8,044 reports, respectively. The most commonly reported SOCs for both drugs were general disorders and administration site conditions. Subgroup analyses indicated that the most commonly reported SOC signals among health professionals and non-health professionals remained consistent across both medications. At the preferred term (PT) level, consistent with the drug labeling, the common AEs for anakinra and canakinumab included injection site reactions (ISRs) and infections. Further analysis revealed a higher frequency of ISRs with anakinra, including injection site pain and erythema. In contrast, canakinumab was associated with more gastrointestinal disorders (abdominal pain, mouth ulceration, and inflammatory bowel disease) and respiratory disorders (cough, oropharyngeal pain, and rhinorrhea); these conditions predominantly occurred among minors. Notably, no significant safety signals related to tuberculosis infection or reactivation were observed, and the frequency of AEs related to hepatic injury and malignancy was low.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study confirms the favorable safety profiles of anakinra and canakinumab, offering critical insights into rational drug usage and safety regulations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1483669","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T07:25:12Z","timestamp":1745997912000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system"],"prefix":"10.3389","volume":"16","author":[{"given":"Hao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"888392","DOI":"10.3389\/fimmu.2022.888392","article-title":"Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders","volume":"13","author":"Arnold","year":"2022","journal-title":"Front. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.55563\/clinexprheumatol\/815tdt","article-title":"Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients","volume":"132","author":"Atas","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.3390\/jcm11195799","article-title":"Anakinra for the treatment of hemophagocytic lymphohistiocytosis: 21 cases","volume":"11","author":"Baverez","year":"2022","journal-title":"J. Clin. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1055\/s-0031-1275398","article-title":"Clinical benefits of intra-articular anakinra for persistent knee effusion","volume":"24","author":"Brown","year":"2011","journal-title":"J. Knee Surg."},{"key":"B5","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3928\/01477447-20101021-09","article-title":"Clinical benefits of intra-articular anakinra for arthrofibrosis","volume":"33","author":"Brown","year":"2010","journal-title":"Orthopedics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.rbre.2016.10.001","article-title":"Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies","volume":"56","author":"Cabral","year":"2016","journal-title":"Rev. Bras. Reumatol. Engl. Ed."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","article-title":"Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et\u2019s disease","volume":"14","author":"Cantarini","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/art.24096","article-title":"Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study","volume":"61","author":"Chevalier","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/14712598.2023.2282133","article-title":"The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study","volume":"23","author":"Co\u015fkuner","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.semarthrit.2021.08.007","article-title":"Efficacy and safety of canakinumab in the treatment of adult-onset Still\u2019s disease: a systematic review","volume":"51","author":"Cota-Arce","year":"2021","journal-title":"Semin. Arthritis Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"998281","DOI":"10.3389\/fmed.2022.998281","article-title":"Off-label use of canakinumab in pediatric rheumatology and rare diseases","volume":"9","author":"Del Giudice","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab","volume":"2","author":"Dhimolea","year":"2010","journal-title":"Mabs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jbspin.2019.07.011","article-title":"Infectious adverse events in children with juvenile idiopathic arthritis treated with biological agents in a real-life setting: data from the JIRcohorte","volume":"87","author":"Dumaine","year":"2020","journal-title":"Jt. Bone Spine"},{"key":"B15","first-page":"668","article-title":"Efficacy and safety of canakinumab in patients with Still\u2019s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups","volume":"36","author":"Feist","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","article-title":"The evolving role of disproportionality analysis in pharmacovigilance","volume":"23","author":"Fusaroli","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/jrheum.210563","article-title":"Anakinra in patients with systemic juvenile idiopathic arthritis: long-term safety from the pharmachild registry","volume":"49","author":"Giancane","year":"2022","journal-title":"J. Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/14397595.2018.1559488","article-title":"Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients","volume":"30","author":"G\u00fclez","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/mr\/roac128","article-title":"Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: results from an open-label Phase III study","volume":"33","author":"Iwata","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00296-011-2096-3","article-title":"Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations","volume":"32","author":"Kaiser","year":"2012","journal-title":"Rheumatol. Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2024.2386370","article-title":"Long-term safety profile and secondary effectiveness of canakinumab in pediatric rheumatic diseases: a single-center experience","volume":"1","author":"Kilic Konte","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.4110\/in.2024.24.e21","article-title":"IL-1 receptor dynamics in immune cells: orchestrating immune precision and balance","volume":"24","author":"Kim","year":"2024","journal-title":"Immune Netw."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/rheumatology\/kew208","article-title":"Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes","volume":"55","author":"Kullenberg","year":"2016","journal-title":"Rheumatol. Oxf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e2022084","DOI":"10.1590\/1984-0462\/2024\/42\/2022084","article-title":"Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review","volume":"42","author":"Lima","year":"2023","journal-title":"Rev. Paul. Pediatr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"105299","DOI":"10.1016\/j.jbspin.2021.105299","article-title":"Anakinra effectiveness in refractory polyserositis: an Italian multicenter study","volume":"89","author":"Lopalco","year":"2022","journal-title":"Jt. Bone Spine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12969-023-00891-y","article-title":"Anakinra and hepatotoxicity in pediatric rheumatology: a case series","volume":"21","author":"Martins","year":"2023","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/pds.1058","article-title":"The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions","volume":"14","author":"Moore","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1093\/rheumatology\/keab202","article-title":"Severe hepatotoxicity as a rare side effect of anakinra in a patient with systemic JIA","volume":"60","author":"Murray","year":"2021","journal-title":"Rheumatol. Oxf."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.autrev.2014.08.031","article-title":"Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study","volume":"13","author":"N\u00e9el","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5152\/TurkArchPediatr.2024.23221","article-title":"How safe are biological agents in pediatric rheumatology?","volume":"59","author":"Nur Sunar Yayla","year":"2024","journal-title":"Turk Arch. Pediatr."},{"key":"B32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12969-024-00974-4","article-title":"Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience","volume":"22","author":"Qiu","year":"2024","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-015-0228-7","article-title":"Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey","volume":"10","author":"Rossi-Semerano","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","article-title":"Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials","volume":"77","author":"Ruperto","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.avsg.2022.05.024","article-title":"Genetic and pharmacological disruption of interleukin-1\u03b1 leads to augmented murine aortic aneurysm","volume":"85","author":"Salmon","year":"2022","journal-title":"Ann. Vasc. Surg."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1339337","DOI":"10.3389\/fimmu.2023.1339337","article-title":"Efficacy and safety of anakinra and canakinumab in PSTPIP1-associated inflammatory diseases: a comprehensive scoping review","volume":"14","author":"Sanz-Cabanillas","year":"2023","journal-title":"Front. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1162742","DOI":"10.3389\/fphar.2023.1162742","article-title":"Continuous IV infusion of anakinra","volume":"14","author":"Saunders","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s10067-018-4119-x","article-title":"Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study","volume":"37","author":"Sota","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00228-020-02909-w","article-title":"Borrowing external information to improve Bayesian confidence propagation neural network","volume":"76","author":"Tada","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/phar.1677","article-title":"Anakinra-induced acute liver failure in an adolescent patient with Still's disease","volume":"36","author":"Taylor","year":"2016","journal-title":"Pharmacotherapy"},{"key":"B45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.semarthrit.2015.02.006","article-title":"Anakinra for the treatment of acute severe gout in critically ill patients","volume":"45","author":"Thueringer","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"B46","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fphar.2016.00380","article-title":"A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study","volume":"7","author":"Vitale","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/iub.2568","article-title":"Roles of IL-1 and IL-10 family cytokines in the progression of systemic lupus erythematosus: friends or foes?","volume":"74","author":"Wu","year":"2022","journal-title":"IUBMB Life"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.2147\/JIR.S474879","article-title":"Role of IL-1 family cytokines IL-36, IL-37, IL-38 in osteoarthritis and rheumatoid arthritis: a comprehensive review","volume":"17","author":"Xu","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1338902","DOI":"10.3389\/fphar.2024.1338902","article-title":"Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database","volume":"15","author":"Zou","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1483669\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T07:25:13Z","timestamp":1745997913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1483669\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":49,"alternative-id":["10.3389\/fphar.2025.1483669"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1483669","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"article-number":"1483669"}}